These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2277318)

  • 1. Development of a parenteral formulation of trimelamol, a synthetic S-triazine carbinolamine-containing cytotoxic agent.
    Gibson M; Denham AJ; Taylor PM; Payne NI
    J Parenter Sci Technol; 1990; 44(6):306-13. PubMed ID: 2277318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M.
    Krishna G; Hodnick WF; Lang W; Lin X; Karra S; Mao J; Almassian B
    AAPS PharmSciTech; 2001 Aug; 2(3):E14. PubMed ID: 14727873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
    Prabhu S; Ortega M; Ma C
    Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.
    Nuijen B; Bouma M; Henrar RE; Floriano P; Jimeno JM; Talsma H; Kettenes-van den Bosch JJ; Heck AJ; Bult A; Beijnen JH
    PDA J Pharm Sci Technol; 2000; 54(3):193-208. PubMed ID: 10927911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P [6-11].
    Jonkman-de Vries JD; Rosing H; Talsma H; Henrar RE; Kettenes-van den Bosch JJ; Bult A; Beijnen JH
    Invest New Drugs; 1998; 16(2):99-111. PubMed ID: 9848573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removal of peroxides in polyethylene glycols by vacuum drying: implications in the stability of biotech and pharmaceutical formulations.
    Kumar V; Kalonia DS
    AAPS PharmSciTech; 2006 Jul; 7(3):62. PubMed ID: 17025243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems.
    Cirri M; Mura P; Mora PC
    Int J Pharm; 2007 Aug; 340(1-2):84-91. PubMed ID: 17531411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parenteral formulation development for the positive inotropic agent RS-82856: solubility and stability enhancement through complexation and lyophilization.
    Visor GC; Lin LH; Benjamin E; Strickley RG; Gu L
    J Parenter Sci Technol; 1987; 41(4):120-5. PubMed ID: 3668754
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9.
    Jonkman-de Vries JD; Talsma H; Henrar RE; Kettenes-van den Bosch JJ; Bult A; Beijnen JH
    Cancer Chemother Pharmacol; 1994; 34(5):416-22. PubMed ID: 8070009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the stability of trimelamol, a carbinolamine-containing antitumor drug.
    Jackson C; Crabb TA; Gibson M; Godfrey R; Saunders R; Thurston DE
    J Pharm Sci; 1991 Mar; 80(3):245-51. PubMed ID: 2051341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346.
    Van der Schoot SC; Nuijen B; Sood P; Thurmond KB; Stewart DR; Rice JR; Beijnen JH
    Pharmazie; 2006 Oct; 61(10):835-44. PubMed ID: 17069422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relating solubility data of parabens in liquid PEG 400 to the behaviour of PEG 4000-parabens solid dispersions.
    Unga J; Tajarobi F; Norder O; Frenning G; Larsson A
    Eur J Pharm Biopharm; 2009 Oct; 73(2):260-8. PubMed ID: 19508891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraorally fast-dissolving particles of a poorly soluble drug: preparation and in vitro characterization.
    Laitinen R; Suihko E; Toukola K; Björkqvist M; Riikonen J; Lehto VP; Järvinen K; Ketolainen J
    Eur J Pharm Biopharm; 2009 Feb; 71(2):271-81. PubMed ID: 18824096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery.
    Soga O; van Nostrum CF; Fens M; Rijcken CJ; Schiffelers RM; Storm G; Hennink WE
    J Control Release; 2005 Mar; 103(2):341-53. PubMed ID: 15763618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Freeze-dried formulations for in vivo gene delivery of PEGylated polyplex micelles with disulfide crosslinked cores to the liver.
    Miyata K; Kakizawa Y; Nishiyama N; Yamasaki Y; Watanabe T; Kohara M; Kataoka K
    J Control Release; 2005 Dec; 109(1-3):15-23. PubMed ID: 16298011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11).
    Hirakura Y; Kojima S; Okada A; Yokohama S; Yokota S
    Int J Pharm; 2004 Nov; 286(1-2):53-67. PubMed ID: 15501002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of lyophilization on the stability of liposomes containing 5-FU.
    Glavas-Dodov M; Fredro-Kumbaradzi E; Goracinova K; Simonoska M; Calis S; Trajkovic-Jolevska S; Hincal AA
    Int J Pharm; 2005 Mar; 291(1-2):79-86. PubMed ID: 15707734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micellar complexes of all-trans retinoic acid with polyvinylalcohol-nicotinoyl esters as new parenteral formulations in neuroblastoma.
    Zuccari G; Bergamante V; Carosio R; Gotti R; Montaldo PG; Orienti I
    Drug Deliv; 2009 May; 16(4):189-95. PubMed ID: 19241235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the degradation pathway of a poorly water-soluble drug formulated in PEG-400.
    Kochling JD; Miao H; Young CR; Looker AR; Shannon M; Montgomery ER
    J Pharm Biomed Anal; 2007 Apr; 43(5):1638-46. PubMed ID: 17224256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.
    Nuijen B; Bouma M; Talsma H; Manada C; Jimeno JM; Lopez-Lazaro L; Bult A; Beijnen JH
    Drug Dev Ind Pharm; 2001 Sep; 27(8):767-80. PubMed ID: 11699828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.